Summary & Overview
HCPCS Q4182: Transcyte, Biologic Skin Substitute per cm2
HCPCS Level II code Q4182 designates Transcyte billed per square centimeter as an add-on supply for biologic skin substitute applications. It matters nationally because biologic dressings are common in complex wound and burn management, influence supply and procedure-line reimbursement, and affect clinical workflows across inpatient and outpatient acute care settings.
Key national payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical role and billing context, common payer coverage patterns, and typical settings where Transcyte is used.
This publication summarizes what the code represents, outlines the service line implications for hospitals and wound care centers, and highlights operational considerations for billing Transcyte as an add-on supply. It also identifies where supplemental information is needed: associated taxonomies, specific ICD-10 diagnoses, and related codes are not provided in the input and are noted as unavailable. The content is aimed at revenue cycle managers, hospital billing staff, and clinical administrators seeking a clear, national-level briefing on HCPCS Level II code Q4182.
Billing Code Overview
HCPCS Level II code Q4182 represents Transcyte, billed per square centimeter as an add-on supply or biological dressing item to be listed separately in addition to a primary procedure. The service type is a biologic skin substitute application used for wound coverage and temporary biologic dressing. The typical site of service is acute care settings where wound management occurs, such as hospital inpatient units, hospital outpatient departments, and specialized burn or wound care centers.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A middle-aged patient with a partial-thickness thermal burn to the forearm presents to a hospital-based burn center for definitive wound management. Initial evaluation in the emergency department includes wound cleansing, debridement of nonviable tissue, pain control, tetanus update as indicated, and dressing application. After assessment by the burn surgeon, the patient is scheduled for application of a biologic skin substitute, TransCyte, to accelerate epithelialization of the partial-thickness burn. The clinical workflow includes operative or procedure-suite preparation, topical antimicrobial management, measurement of the wound in square centimeters to determine product units, sterile application of the TransCyte graft material to the prepared wound bed, securement with appropriate dressings, and documentation of product lot number and area treated. Post-application care includes outpatient or inpatient wound checks, dressing changes, and follow-up to assess graft take and healing. Typical sites of service include hospital outpatient departments, inpatient hospital wards, ambulatory surgery centers, and specialized burn clinics. Common clinical goals are pain reduction, infection control, and promotion of re-epithelialization for partial-thickness burns, donor sites, and similar superficial wounds where TransCyte is indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard billing | Use when no special circumstance or modifier applies to the TransCyte add-on charge. |